Novartis Highlights Immunology Pipeline Progress at EULAR 2026
BASEL, Switzerland, June 1, 2026 Novartis announced that it will present new data from 31 abstracts across its expanding...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BASEL, Switzerland, June 1, 2026 Novartis announced that it will present new data from 31 abstracts across its expanding...
BASEL, Switzerland, May 21, 2026 Novartis announced it will present more than 65 company-sponsored and investigator-sponsored abstracts at the...
